Market Cap (In USD)
3.18 Billion
Revenue (In USD)
8.08 Million
Net Income (In USD)
-58.29 Million
Avg. Volume
584.25 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 7.79-71.71
- PE
- -
- EPS
- -
- Beta Value
- 3.517
- ISIN
- US47103J1051
- CUSIP
- 47103J105
- CIK
- 1817713
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. David Alan Campbell Ph.D.
- Employee Count
- -
- Website
- https://www.januxrx.com
- Ipo Date
- 2021-06-11
- Details
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
More Stocks
-
LORDSCHLOLords Chloro Alkali Limited
LORDSCHLO
-
PASUSPG
-
PLFF
-
000428Huatian Hotel Group Co.,Ltd.
000428
-
AFP
-
MSSV
-
JOBS
-
SCCO